

8/1/2023

Recent Drug Formulary Updates: Effective August 15th, 2023

- Added to formulary without a PA
 - Combivent Respimat (there is a concurrent therapy edit to prevent duplication of therapy with other SABAs, SAMAs, or LAMAs)
 - Atrovent HFA (there is a concurrent therapy edit to prevent duplication of therapy with other SAMAs or LAMAs)
 - Levalbuterol HFA (there is a concurrent therapy edit to prevent duplication of therapy with other SABAs)
 - Loperamide 2mg tablets, 1mg/5ml solution, and 1mg/7.5ml solution
 - Bisacodyl 5mg tablets, 5mg DR tablets, and 10mg suppositories
 - Donepezil IR 5mg, 10mg and 27mg
 - Estradiol 0.025mg/24hr patch
 - Pregabalin IR capsules (max daily dose 600mg for all strengths)
 - Lacosamide tablets
 - Xarelto 2.5mg allowing 90 days before PA required

- Changes
 - Mupirocin 2% ointment allowing up to 3 fills (66 grams total) per 180 days for ages 20 and younger
 - Albuterol HFA allowing 2 inhalers per 30 days
 - Buprenorphine and buprenorphine/naloxone has max daily dose of 32mg
 - Stiolto Respimat and Anoro Ellipta added to step therapy after trial of Incruse Ellipta
 - Methylphenidate ER 18mg, 27mg, 36mg, 54mg, and 72mg added to step therapy after methylphenidate ER 10mg or 20mg tablets (ages 22 and younger only)
 - Ondansetron IR tablets and ODT have max daily dose of 24 mg